Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Giora Sharf"'
Autor:
Martin H. Ellis, Tamar Tadmor, Naama Yekutiel, Gabriel Chodick, Moti Levy, Giora Sharf, Nana Ben Zvi, Raanan Leef, Oren Feine, Oren Shavit
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 12, p 3390 (2024)
Background/Objectives: Polycythemia vera (PV) is a chronic hematologic neoplasm commonly treated with hydroxyurea (HU). We utilized the advanced digitalized database of Maccabi Healthcare Services to retrospectively investigate the clinical and econo
Externí odkaz:
https://doaj.org/article/87abb7d1d23c4ca98856ce78e414fc7e
Autor:
Adi Shacham Abulafia, Sivan Shemesh, Lena Rosenmann, Tamar Berger, Avi Leader, Giora Sharf, Pia Raanani, Uri Rozovski
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 11, p 3417 (2020)
The life expectancy of patients with chronic myeloid leukemia (CML) approaches that of the age-matched population and quality of life (QOL) issues are becoming increasingly important. To describe patients’ characteristics and assess QOL, we deliver
Externí odkaz:
https://doaj.org/article/418ecfa97134449fba3704b70c97f3e0
Autor:
Delphine Réa, Carla Boquimpani, Michael J. Mauro, Yosuke Minami, Alex Allepuz, Vikalp Kumar Maheshwari, Denise D’Alessio, Ying Wu, Rachael Lawrance, Sarunas Narbutas, Giora Sharf, Andreas Hochhaus
Publikováno v:
Leukemia. 37:1060-1067
In ASCEMBL, an open-label, randomized Phase 3 study, asciminib demonstrated superior efficacy and better safety profile compared with bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine
Publikováno v:
Supportive Care in Cancer
Background: The COVID-19 pandemic required reevaluation of the therapeutic approach and added emotional stress for patients with hematological malignancies at high risk of contracting the virus. We aimed to evaluate how it affected such patients duri
Autor:
Massimo Breccia, Anna Turkina, Carla Boquimpani, Charles Chuah, Giora Sharf, Luigi Di Caprio, Matthias Hoch, Justin Yssel, Yifan Zhang, Andreas Hochhaus
Publikováno v:
Blood. 140:9635-9636
Autor:
Pia Raanani, Giora Sharf
Publikováno v:
Acta Haematologica. 143:1-4
Autor:
Pia Raanani, Sabina De Geest, Juliet Dreyer, Eric Tousset, Osnat Yarchovsky-Dolberg, Martin Ellis, Itai Levi, Anat Gafter-Gvili, Opher Caspi, Alina Amitai, Giora Sharf, Avi Leader, Bronya Calvarysky, Noam Benyamini
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:e449-e461
Background Nonadherence to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has been associated with inferior outcomes. Scarce evidence exists on the effectiveness of adherence-enhancing interventions. The present pilot study evalu
Autor:
Avi Leader, Adi Abulafia, Tamar Berger, Lena Rosenmann, Giora Sharf, Sivan Shemesh, Pia Raanani, Uri Rozovski
Publikováno v:
Journal of Clinical Medicine
Volume 9
Issue 11
Journal of Clinical Medicine, Vol 9, Iss 3417, p 3417 (2020)
Volume 9
Issue 11
Journal of Clinical Medicine, Vol 9, Iss 3417, p 3417 (2020)
The life expectancy of patients with chronic myeloid leukemia (CML) approaches that of the age-matched population and quality of life (QOL) issues are becoming increasingly important. To describe patients&rsquo
characteristics and assess QOL, we
characteristics and assess QOL, we
Autor:
Anat Gafter-Gvili, Avi Leader, Pia Raanani, Opher Caspi, Alina Amitai, Eric Tousset, Bronya Calvarysky, Osnat Yarchovsky-Dolberg, Noam Benyamini, Martin Ellis, Itai Levi, Sabina De Geest, Juliet Dreyer, Giora Sharf
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:e351-e362
Background There are inconsistencies in reports on correlates for nonadherence (NA) to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). The diagnostic accuracy of subjective adherence measures using electronic monitoring (EM) as t
Autor:
Felice Bombaci, Nigel B. Deekes, Jennifer A. Bradley, Bahija Gouimi, Jan Geissler, Zack Pemberton-Whiteley, Rita I O Christensen, Giora Sharf, Celia Marin, Mina Daban
Publikováno v:
Leukemia
In CML, treatment-free remission (TFR) refers to having a stable deep molecular response without the need for ongoing tyrosine kinase inhibitor treatment. Whilst recommendations exist about the technical management of stopping and re-starting therapy